Latest News On Louisiana

Latest California Healthline Stories

KFF Health News' 'What the Health?': Anti-Abortion Hard-Liners Speak Up

While Republican candidates in many states downplay their opposition to abortion, the most vehement wing of the movement, which helped overturn Roe v. Wade — those who advocate prosecuting patients, outlawing contraception, and banning IVF — are increasingly outspoken. Meanwhile, some state legislatures continue to advance new restrictions, like a proposal moving in Louisiana to include abortion medications mifepristone and misoprostol on the list of the most dangerous drugs. Alice Miranda Ollstein of Politico, Rachel Roubein of The Washington Post, and Joanne Kenen of the Johns Hopkins schools of public health and nursing and Politico Magazine join KFF Health News’ Julie Rovner to discuss these stories and more. Also this week, Rovner interviews Shefali Luthra of The 19th about her new book on abortion in post-Roe America, “Undue Burden.”

Empresas de capital riesgo invierten en el negocio de los ensayos clínicos de medicamentos. ¿Cuál es el riesgo para los pacientes?

Para lanzar un nuevo fármaco al mercado, la Administración de Alimentos y Medicamentos (FDA) exige a las farmacéuticas estudios exhaustivos para demostrar su seguridad y eficacia. Conseguir que un medicamento salga al mercado unos meses antes, y con menos gastos de lo habitual, puede traducirse en beneficios millonarios para el fabricante.